10x Genomics, Inc.TXG

The most striking development in the 10x Genomics file this month is not a product launch but a flurry of insider transactions. Between 8 June and 24 June 2026, multiple Form 4 filings and a Form 144 landed on SEC EDGAR, documenting share disposals by officers and directors. The sales are not enormous in dollar terms, but the timing is notable: they arrive against a March quarter that produced a net loss of $13.5 million on $150.8 million in revenue, with an operating loss of $17 million and diluted EPS of negative $0.10. When the people running the lab are selling, it sharpens the question of when the platform story will turn profitable.

10x Genomics makes instruments and consumables for single cell and spatial biology research. Its Chromium platform and the newer GEM X Flex family let laboratories profile thousands of individual cells from fresh, frozen, or fixed samples, including the difficult FFPE blocks that sit in hospital archives. The Visium spatial assays add a layer of tissue mapping, so researchers can see where genes are active inside a slice of tumour or brain. The product pages are detailed, and the compatible products rail lists verified reagents from BioLegend, IDT, and Miltenyi, which suggests a functioning ecosystem. Still, the company's financials show that selling this ecosystem remains a money consuming exercise.

According to the 10-Q for the period ending 31 March 2026, total assets were $1.02 billion and stockholders' equity was $814.3 million, with liabilities at $201.4 million. Cash from operations was a positive $26.1 million, and capital expenditure on property and equipment was just $1.6 million, so the business is not bleeding cash through heavy infrastructure spend. Inventory stood at $53.5 million, with a $2.7 million decrease over the period, hinting at destocking rather than inventory build. The weighted average diluted share count was 128.3 million, and with losses continuing, further dilution remains a live risk for existing holders.

The GEM X Flex family is the headline product push, and the official rail claims it is redefining single cell work with a plate based transformation that unlocks game changing scale. The Chromium technology page reminds visitors that over $1.5 billion in R&D went into the microfluidic chip architecture. That investment is real and visible in the product range, but the filed numbers show it has not yet translated into sustained net profitability. The compatible products page is a useful signal of third-party validation, but it does not fill the gap between a $150.8 million quarterly revenue run rate and a bottom line that remains in the red.

What changed this period is the insider selling, not the financial trajectory. The loss narrowed compared with prior quarters, but the company is still not generating net income. The evidence does not include a new product approval, a major contract, or a guidance upgrade. The file is therefore shaped by what is present: a well-capitalised research tools company with a strong asset base, a persistent quarterly loss, and a board that has chosen this moment to lighten its personal exposure. A future filing showing a turn to net profit, or a material jump in revenue, would change the character of the story entirely.